



# Biotech Daily

Tuesday May 23, 2023

*Daily news on ASX-listed biotechnology companies*

- \* **ASX EVEN, BIOTECH DOWN: COMPUMEDICS UP 13%; CYNATA DOWN 13%**
- \* **4D MEDICAL UNVEILS CT VENTILATION, PERFUSION IMAGING**
- \* **AND HEALTH: SOUTH AUSTRALIA BACKS DIGITAL HEALTH**
- \* **DIRECTOR GUY HEADLEY REDUCES TO 20.2% IN VITURA**
- \* **FORMER DIRECTOR DR BERNARD HOCKINGS BELOW 5% IN PYC**
- \* **ANTHONY BARTON BELOW 5% IN PYC**
- \* **BIO-MELBOURNE MEDTECH MANUFACTURING NEXT WEEK**

## MARKET REPORT

The Australian stock market slipped 0.05 percent on Tuesday May 23, 2023, with the ASX200 down 3.4 points to 7,259.9 points.

Ten of the Biotech Daily Top 40 stocks were up, 20 fell, eight traded unchanged and two were untraded.

Compumedics was the best, up two cents or 13.3 percent to 17 cents, with 500 (five hundred) shares traded. Actinogen climbed 5.45 percent; Micro-X and Telix were up more than three percent; Clinuvel, Kazia and Medical Developments rose more than two percent; Alcidion and Avita were up more than one percent; with CSL, Pro Medicus and Resmed up by less than one percent.

Cynata led the falls, down two cents or 13.3 percent to 13 cents, with 1.4 million shares traded.

Universal Biosensors lost 7.55 percent; Genetic Signatures was down 6.7 percent; Starpharma shed 5.5 percent; Resonance fell 4.8 percent; Amplia, Opthea and Proteomics were down more than three percent; Nanosonics, Neuren, Nova Eye and Prescient shed more than two percent; Antisense, Cyclopharm, Immutep, Mesoblast, Next Science, Orthocell and Paradigm were down more than one percent; with Cochlear and Polynovo down by less than one percent.

## 4D MEDICAL

4D Medical says it has developed the CT:VQ computed tomography ventilation and perfusion software to image lung dynamics without radioactive tracers or contrast media. 4D Medical said that using “non-contrast paired inspiratory-expiratory computed tomography scans” it allowed for the extraction of quantitative perfusion data and visualizations of blood flow in the lungs.

The company said the software was able to measure regional ventilation and perfusion changes and assess local density changes to quantify regional blood-mass change.

4D Medical said that in a healthy lung, ventilation and perfusion were well-matched, meaning that airflow and blood flow were evenly distributed throughout the lungs.

“However, in certain lung conditions there can be a mismatch between [ventilation and perfusion], indicating abnormalities in lung function, and in the most severe cases this can be life threatening,” the company said.

4D Medical said the software allowed for a detailed assessment of ventilation and perfusion mismatch.

The company said that computed tomography scans were used primarily for diagnosing and managing pulmonary embolisms, but could be used to assess chronic obstructive pulmonary disease, pulmonary hypertension, lung parenchymal diseases and pulmonary vascular disorders.

4D Medical said that acute pulmonary embolus was a serious, but difficult, diagnosis for clinicians, where pulmonary perfusion was “a critical component to aid diagnosis”.

The company said that current imaging used computed tomography pulmonary angiography which measured pulmonary arterial flow blockages and nuclear medicine ventilation and perfusion scans, which assessed the mismatch in ventilation and perfusion.

4D Medical said that both systems required intravenous contrast media, with nuclear imaging requiring the inhalation of a radioactive contrast agent.

The company said its CT:VQ computed tomography ventilation and perfusion software would lower costs to hospitals as it did not require “the capital expenditure involved in mitigating radiation risks of operating a nuclear medicine [ventilation and perfusion] scanners, such as specialized facilities for preparing, handling and disposing of radioactive materials”.

4D Medical said it presented early clinical data from the technology at the American Thoracic Society meeting in Washington, DC on May 22, 2023 and said it was a “significant technological breakthrough and milestone”.

4D Medical managing-director Prof Andreas Fouras said: “Today, 4D Medical announces another significant achievement extending our capabilities beyond ventilation, and into perfusion”.

Prof Fouras said the progress made on the CT-VQ software meant that the company was on-track to file a submission for approval to the US Food and Drug Administration by the end of this year.

Prof Fouras said that depending on the FDA response time “we expect to be in the US market around the middle of calendar 2024”.

“In a matter of years, XV technology has set the scene for a step-change in respiratory imaging, measuring regional airflow with sensitivity far beyond the limitations of existing modalities, that in some cases have been in use for over a century,” Prof Fouras said.

“Together, regional ventilation and perfusion will provide a complete picture of lung health,” Prof Fouras said.

4D Medical fell 1.5 cents or 1.65 percent to 89.5 cents with 2.1 million shares traded.

## AUSTRALIAN NATIONAL DIGITAL HEALTH, SOUTH AUSTRALIA GOVERNMENT

AND Health says the South Australian Minister for Health and Wellbeing Chris Picton has supported the industry at its Digital Health Summit in Adelaide.

AND Health said at a meeting of 70 digital health industry executives Mr Picton addressed the importance of the sector in South Australia and the support needed at the State Government level to improve local procurement.

AND Health said the 33 operational South Australian digital health companies in its digital health database had a median total funding from 2017-'23 of \$300,000 with 68 percent of the companies having raised less than \$500,000.

AND Health chief executive officer Bronwyn Le Grice said the number of South Australian digital health companies had increased three-fold over the last three years, which showed "the huge potential for further acceleration of the local sector".

Mr Picton said that with the increased demands on the healthcare system "it's the right time to consider what outcomes we can achieve through digital technologies and ensure they remained aligned to the broader system priorities".

"To build on the achievements of digital health in South Australia to date, we need a digital health strategy that is not just aspirational but is also realistic and achievable," Mr Picton said.

"And while [artificial intelligence] has a role to play in healthcare delivery, we need to ensure digital health innovation is designed in conjunction with the healthcare workforce based on what they require to provide the best possible care for patients," Mr Picton said.

"I acknowledge there is more work we need to do as a State Government for local digital health companies to have the best chance at winning local procurement of digital health work," Mr Picton said.

## VITURA HEALTH

Vitura director Guy Headley says he has reduced his substantial shareholding from 128,952,151 shares (23.51%) to 112,202,151 shares (20.16%).

The Robina, Queensland-based Mr Headley said that he and his partner Jessimine Jansen exercised 2,000,000 performance rights into shares between December 31, 2021 and December 22, 2022; and on May 19, 2023 he sold 18,750,000 shares at 32 cents a share (BD: May 22, 2023).

Vitura fell 1.5 cents or 4.2 percent to 34 cents.

## PYC THERAPEUTICS

PYC former director Dr Bernard Hockings says he has ceased his substantial holding with an off-market transfer and share sale and by being diluted in a recent placement.

The Brunswick, Western Australia-based Dr Hockings said that on December 15, 2022 he transferred 31,800,000 shares off-market, on May 19, 2023 he sold 8,333,333 shares off-market for \$550,000, or 6.6 cents a share and was diluted to 4.67 percent.

In 2021, Dr Hockings said he had reduced his holding to 199,835,396 shares or 6.3 percent of the company (BD: Jan 16, 2022).

Earlier this month, PYC said that it had raised \$30 million in a placement at 5.5 cents a share (BD: May 11, 2023).

PYC was up 0.1 cents or 1.7 percent to 5.9 cents.

## PYC THERAPEUTICS

Anthony Barton and associates say their 155,200,314 substantial share-holding in PYC has been diluted to 4.54 percent following the recent placement (see above).

In 2020, the Perth-based Anthony Barton and associates said they held 155,200,314 shares or 5.3 percent of the company (BD: Mar 23, 2020).

## BIO-MELBOURNE NETWORK

The Bio-Melbourne Network says its masterclass program on medical technology manufacturing begins next week.

The Bio-Melbourne Network said the Masterclass was titled 'Conception to Creation: The Roadmap to Medtech Manufacturing' and would guide participants through the manufacturing pipeline, and discuss manufacturing lessons for start-ups, cultivating a medical device supply chain, manufacturing best practices and designing processes and procedures.

The Network said that the masterclass was sponsored by the Victoria Government and would include the Haifa, Israel-based Memed's head of research and development Dr Oren Zarchin.

The industry organization said the Masterclass included a tour of Invetech's ISO13485 approved Mount Waverley factory.

Bio-Melbourne said the program had three parts, a forum at the Australian Centre for the Moving Image in Flinders Street, Melbourne on May 30, 2023 from 7.30am to 10am (AEST); a workshop at Invetech on May 31 from 8.30am to 5.30pm; and a 30-minute individual advisory session on June 1 and 2, 2023.

For details and registration, go to: <https://bit.ly/4135ixq>.